Highly Cited Collection
Browse a collection of some of the most highly cited articles, published in IBD (Inflammatory Bowel Diseases). This is just a small sample of the outstanding research published by the journal, that is making an impact.
Jonathan Golob and others
Inflammatory Bowel Diseases, Volume 31, Issue 3, March 2025, Pages 763–776, https://doi.org/10.1093/ibd/izae238
Even in the absence of inflammation, persistent symptoms in patients with Crohn’s disease (CD) are prevalent and worsen quality of life. We previously demonstrated enrichment in sulfidogenic microbes in quiescent Crohn’s disease patients with (qCD + S) vs without persistent GI symptoms...
Thabet Qapaja and others
Inflammatory Bowel Diseases, izae267, https://doi.org/10.1093/ibd/izae267
Biologics and oral small molecules (OSM) effectively treat inflammatory bowel disease (IBD), but some are linked to higher risks of major adverse cardiovascular events (MACE) and venous thromboembolism (VTE). This study evaluates the MACE and VTE risks in IBD patients...
Bruce E Sands and others
Inflammatory Bowel Diseases, izae253, https://doi.org/10.1093/ibd/izae253
Mirikizumab, a p19-directed interleukin-23 monoclonal antibody, has demonstrated induction of clinical remission at week 12 with maintenance through week 104 in patients with moderately-to-severely active ulcerative colitis (UC). Results are presented from the LUCENT-3 open-label extension study through week 152.
Ariel A Jordan and others
Inflammatory Bowel Diseases, izae237, https://doi.org/10.1093/ibd/izae237
A prior survey disseminated in 2017 identified that healthcare access barriers exist and significantly affect patients with inflammatory bowel disease (IBD). We sought to identify, through an updated survey, the healthcare access barriers that patients continue to face, with a...
Berkeley N Limketkai and others
Inflammatory Bowel Diseases, izae115, https://doi.org/10.1093/ibd/izae115
Prebiotics are nondigestible carbohydrates fermented by gut bacteria into metabolites that confer health benefits. However, evidence on their role for inflammatory bowel disease (IBD) is unclear. This study systematically evaluated the research on prebiotics for treatment of IBD.
Rotem Sigall Boneh and others
Inflammatory Bowel Diseases, Volume 30, Issue 10, October 2024, Pages 1888–1902, https://doi.org/10.1093/ibd/izad255
Dietary therapy is increasingly recognized for the management of Crohn’s disease (CD) over recent years, including the use of exclusive enteral nutrition (EEN) as first-line therapy for pediatric CD according to current guidelines. The Crohn’s disease exclusion diet (CDED) is...
Simon Travis and others
Inflammatory Bowel Diseases, Volume 30, Issue 6, June 2024, Pages 939–949, https://doi.org/10.1093/ibd/izad142
The Communicating Needs and Features of IBD Experiences (CONFIDE) study aimed to evaluate the experience and impact of ulcerative colitis (UC) symptoms on patients’ lives and elucidate gaps in communication between patients and health care professionals (HCPs).
Shubha Bhat and others
Inflammatory Bowel Diseases, Volume 30, Issue 5, May 2024, Pages 829–843, https://doi.org/10.1093/ibd/izad120
The recent approval of new medications with novel mechanisms of action and emergence of updated safety information for existing therapies has changed the treatment landscape of inflammatory bowel disease (IBD). These advances led to unique adverse effect profiles and identification...
Thomas C Mules and others
Inflammatory Bowel Diseases, Volume 30, Issue 5, May 2024, Pages 735–745, https://doi.org/10.1093/ibd/izad110
Human hookworm has been proposed as a treatment for ulcerative colitis (UC). This pilot study assessed the feasibility of a full-scale randomized control trial examining hookworm to maintain clinical remission in patients with UC.
Gut Microbiota Composition in Long-Remission Ulcerative Colitis is Close to a Healthy Gut Microbiota
Claudia Herrera-deGuise and others
Inflammatory Bowel Diseases, Volume 29, Issue 9, September 2023, Pages 1362–1369, https://doi.org/10.1093/ibd/izad058
Microbiome studies report low gut microbial richness and diversity in ulcerative colitis (UC) patients. We explored whether UC patients who reach long-term clinical, endoscopic, and histological remission show a gut microbial ecosystem that is similar to healthy individuals.
Marla C Dubinsky, MD and others
Inflammatory Bowel Diseases, Volume 28, Issue 9, September 2022, Pages 1375–1385, https://doi.org/10.1093/ibd/izab285
Accelerated infliximab (IFX) induction is often based on clinical parameters as opposed to pharmacokinetics (PK). We aimed to investigate the impact of dashboard-guided optimized induction dosing on IFX durability and immunogenicity in a real-world inflammatory bowel disease (IBD) setting.
Nabil El Hage Chehade, MD and others
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages 808–817, https://doi.org/10.1093/ibd/izac135
Fecal microbiota transplantation (FMT) has been investigated as a treatment option for patients with inflammatory bowel disease with controversial results.
María Chaparro, MD, PhD and others
Inflammatory Bowel Diseases, Volume 28, Issue 11, November 2022, Pages 1725–1736, https://doi.org/10.1093/ibd/izab357
Large real-world-evidence studies are required to confirm the durability of response, effectiveness, and safety of ustekinumab in Crohn’s disease (CD) patients in real-world clinical practice.
Berkeley N Limketkai, MD, PhD and others
Inflammatory Bowel Diseases, Volume 28, Issue 11, November 2022, Pages 1627–1636, https://doi.org/10.1093/ibd/izab335
Existing studies on diet and inflammatory bowel disease (IBD) have largely focused on evaluating the effects of single nutrients or whole predesigned diets but not on evaluating the effects of diverse dietary patterns. This study applied unsupervised methods to identify dietary patterns of individuals with IBD and evaluated their association with symptoms activity.
Andrea Costantino, MD and others
Inflammatory Bowel Diseases, Volume 28, Issue 3, March 2022, Pages 474–478, https://doi.org/10.1093/ibd/izab172
Because patients with inflammatory bowel diseases (IBDs), namely Crohn’s disease (CD) and ulcerative colitis (UC), often require immune-modifying treatment, which might increase the risk of opportunistic infection...
Gina L Guzzo, BSc and others
Inflammatory Bowel Diseases, Volume 28, Issue 7, July 2022, Pages 1112–1122, https://doi.org/10.1093/ibd/izab343
The gut microbiome has been implicated in the pathogenesis of inflammatory bowel disease (IBD). Studies suggest that the IBD gut microbiome is less diverse than that of the unaffected population, a phenomenon often referred to as dysbiosis.
Wenwei Qian PhD and others
Inflammatory Bowel Diseases, Volume 29, Issue 4, April 2023, Pages 602–619, https://doi.org/10.1093/ibd/izac225
Exosomes derived from mesenchymal stem cells have shown therapeutic effects for colitis. As a more clinically accessible resource, the therapeutic potential of exosomes from adipose-derived stem cells (ASCs) has not been fully elucidated, and whether hypoxia precondition could improve the therapeutic effect of ASC-derived exosomes in colitis remains elusive.
Gretchen A Lam, DMD and others
Inflammatory Bowel Diseases, Volume 29, Issue 7, July 2023, Pages 1153–1164, https://doi.org/10.1093/ibd/izac241
One of the prospective sequelae of periodontal disease (PD), chronic inflammation of the oral mucosa, is the development of inflammatory gastrointestinal (GI) disorders due to the amplification and expansion of the oral pathobionts.
Stephanie L Gold, MD and others
Inflammatory Bowel Diseases, Volume 29, Issue 3, March 2023, Pages 423–429, https://doi.org/10.1093/ibd/izac102
Patients with inflammatory bowel disease (IBD) are at an increased risk of malnutrition. The goal of this study was to define the prevalence of malnutrition and micronutrient deficiencies in recently diagnosed IBD patients and to compare the performance of existing malnutrition screening tools in identifying IBD patients at increased risk for malnutrition.
Hui Cao, MD and others
Inflammatory Bowel Diseases, Volume 29, Issue 5, May 2023, Pages 818–829, https://doi.org/10.1093/ibd/izac199
Inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn’s disease, are characterized by chronic idiopathic inflammation of gastrointestinal tract.
Interested in publishing your research?
Inflammatory Bowel Diseases and Crohn's & Colitis 360, are both high-quality, peer-reviewed journals contributing to the field.
Learn about publishing with the journals:
